Log In
Print
BCIQ
Print
Print this Print this
 

ARC-520

  Manage Alerts
Collapse Summary General Information
Company Arrowhead Research Corp.
DescriptionShort interfering RNAs targeting 2 regions of the HBV genome conjugated to N-acetylgalactosamine-polymer and cholesterol ligands using Arrowhead's Dynamic Polyconjugate delivery system
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic HBV infection; Treat HBV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today